5 Questions Your Doctor Should Ask Before Prescribing Weight Loss Medication

Prescriptions for GLP-1 weight loss drugs surged by over 300 percent between 2021 and 2025. With that surge came a significant number of prescriptions written without adequate patient evaluation. A study from JAMA Internal Medicine found that many GLP-1 prescriptions lacked documentation of basic health assessments that should precede treatment. Informed prescribing protects your health and sets you up for better outcomes. Here are five questions a responsible provider should ask.

Have You Tried Structured Lifestyle Interventions First?

GLP-1 drugs are not first-line treatments for mild overweight. Clinical guidelines from the American Association of Clinical Endocrinology recommend that pharmacotherapy be considered only after structured lifestyle interventions (diet, exercise, behavioral modification) have been attempted, or in patients with BMI over 30 (or over 27 with comorbidities). A responsible provider should ask about your history with structured weight loss programs, not to gatekeep medication, but to understand your starting point and ensure the medication is used as an addition to, not a replacement for, lifestyle changes. If you have never tried a structured approach, starting medication and lifestyle changes simultaneously may still be appropriate, but the conversation should happen.

Why it matters for your metabolic age: Patients who combine GLP-1 therapy with lifestyle interventions see larger improvements in blood pressure and blood sugar than those on medication alone, leading to greater metabolic age reductions.

Do You Have Any Conditions That Could Make GLP-1 Drugs Risky?

GLP-1 drugs carry contraindications that must be screened before prescribing. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are absolute contraindications for semaglutide and tirzepatide. A history of pancreatitis, gallbladder disease, severe gastrointestinal conditions, or significant kidney impairment requires careful evaluation. Research from the journal Gastroenterology found that GLP-1 use was associated with an increased risk of pancreatitis and biliary disease. Additionally, patients with a history of eating disorders should be carefully evaluated, as the appetite suppression from GLP-1 drugs could potentially worsen restrictive eating patterns. A thorough medical history and appropriate lab work should precede any prescription.

What Is Your Current Relationship With Food and Exercise?

This question goes beyond clinical history into behavioral readiness. Research from the journal Obesity Reviews found that patients with higher baseline health literacy and behavioral readiness achieved significantly better outcomes on GLP-1 therapy. A prescriber who asks about your eating patterns, exercise habits, stress levels, and support systems can better customize their recommendations and identify potential challenges. For example, a patient with significant emotional eating may benefit from concurrent therapy or counseling. A patient with no exercise background may need a referral to a trainer or physical therapist before starting resistance training.

Why it matters for your metabolic age: Understanding your current habits allows your provider to target the specific behaviors that will improve blood pressure, blood sugar, and BMI alongside the medication.

Are You Prepared for This to Be a Long-Term Commitment?

The weight regain data after GLP-1 discontinuation makes it essential that patients understand the potential for long-term medication use before starting. A responsible provider should discuss whether the patient is financially prepared for ongoing treatment, willing to consider long-term use, and aware of the discontinuation data. Research from the journal Pharmacoeconomics found that patient understanding of treatment duration significantly predicted adherence and outcomes. This conversation also helps set realistic expectations. A patient who expects to take the drug for 6 months and then stop may be disappointed when they learn that maintenance may require ongoing use.

What Comprehensive Monitoring Plan Will Be in Place During Treatment?

GLP-1 therapy should include regular monitoring of body composition (not just weight), metabolic markers (blood sugar, HbA1c, blood pressure, cholesterol), kidney function, nutritional status (especially protein intake, B12, and iron), and mental health. Research from the Lancet Diabetes and Endocrinology found that 18 percent of GLP-1 patients developed nutritional deficiencies during treatment. A prescriber who plans to write a prescription and see you once a year is not providing adequate care. Ask about the monitoring schedule and what specific metrics will be tracked at each visit.

Why it matters for your metabolic age: Comprehensive monitoring ensures that your metabolic health is genuinely improving, not just your weight. Tracking metabolic age alongside treatment provides a clear picture of your overall health trajectory.

Take Ownership of Your Metabolic Health Tracking

Your doctor should be monitoring your health, but you can also track it yourself. Penlago’s free MetaAge calculator uses blood pressure, blood sugar, BMI, and age to give you a metabolic age score in 60 seconds. Use it between doctor visits to stay informed about your metabolic health.

Find out your metabolic age in 60 seconds – free.